351. Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus
- Author
-
Nieves, Gómez León, Gema, Vega, Beatriz, Rodríguez-Vigil Junco, and Carlos, Suevos Ballesteros
- Subjects
Male ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Multidetector Computed Tomography ,Humans ,Female ,Single-Blind Method ,Lymphoma, Large B-Cell, Diffuse ,Prospective Studies ,Middle Aged ,Radiopharmaceuticals ,Aged ,Neoplasm Staging - Abstract
To prospectively compare the accuracy in initial staging and end-of-treatment restaging of diffuse large B-cell lymphoma (DLBCL) between 64-slice multidetector computed tomography (64MDCT) and 18FDG positron emission tomography/computed tomography (18FGD PET/CT) with intravenous contrast injection.Randomised and blind controlled clinical multicentric trial that included biopsy-proven DLBCL patients. Seventy-two patients from five different hospitals in the region of Madrid, Spain, were enrolled in the study between January 2012 and June 2015. Thirty-six were randomly allocated to 18FDG PET/TC and the other 36 to 64MDCT for initial staging and end-of-treatment restaging. A nuclear medicine physician and a radiologist independently analysed 18FDG PET/TC images and reached an agreement post-hoc. 64MDCT images were separately evaluated by a different radiologist. Every set of images was compared to the reference standard that included clinical data, complementary tests and follow-up. The study was approved by participating centres' ethics committees and written informed consent was obtained from all the participants.A good agreement was observed between both diagnostic techniques and the reference standard in initial staging [18FDG PET/CT (k=0.5) and 64MDCT (k=0.6)], although only the 18FDG PET/TC showed a good agreement with the reference standard for the end-of-treatment restaging (k=0.7).In DLBCL, both 18FDG PET/TC and 64MDCT have shown good agreement with the reference standard in initial staging. Nevertheless, 18FDG PET/CT has shown to be superior to 64MDCT in end-of-treatment response assessment.
- Published
- 2017